Antibody-mediated effects against Cryptococcus neoformans: Evidence for interdependency and collaboration between humoral and cellular immunity

Research in Immunology

Volumn 149, Issue 4-5, 1998, Pages 321-333

  Vecchiarelli, A ^a   Casadevall, A ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; RODENT;

EID: 0032078599     PISSN: 09232494     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0923-2494(98)80756-6     Document Type: Article

References (141)

1. Aguirre, K.M. & Johnson, L.L. (1997), A role for B cells in resistance to Cryptococcus neoformans in mice. Infect. Immun., 65, 525-530.
2. Aronson, M. & Kletter, J. (1973), Aspects of the defense against a large-sized parasite, the yeast, Cryptococcus neoformans. Israel. J. Med. Sci., 1, 132-162.
3. Belay, T., Cherniak, R., Kozel, T.R. & Casadevall, A. (1997), Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay. Infect. Immun., 65, 718-728.
4. Bennett, J.E. & Hasenclever, H.F. (1965), Cryptococcus neoformans polysaccharide: studies of serologic properties and role in infection. J. Immunol., 94, 916-920.
5. Blackstock, R. (1996), Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J. Med. Vet. Mycol., 34, 19-30.
6. Briles, D.E., Claffin, J.L., Schroer, K. & Forman, C. (1981), Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature, 294, 88-89.
7. Casadevall, A., Mukherjee, J., Devi, S.J.N., Schneerson, R., Robbins, J.B. & Scharff, M.D. (1992), Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis., 65, 1086-1093.
8. Casadevall, A., DeShaw, M., Fan, M., Dromer, F., Kozel, T.R. & Pirofski, L. (1994), Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect. Immun., 62, 3864-3872.
9. Casadevall, A. (1995), Antibody immunity and invasive fungal infections. Infect. Immun., 63, 4211-4218.
10. L usage in polysaccharide binding antibodies. J. Exp. Med., 174, 151-160.
11. Chaka, W., Verheul, A.F.M., Vaishnav, V.V., Cherniak, R., Scharringa, J., Verhoef, J., Snippe, H. & Hoepelman, I.M. (1997), Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells. Infect. Immun., 65, 272-278.
12. Chen, L.-C., Blank, E. & Casadevall, A. (1996), Extracellular proteinase activity of Cryptococcus neoformans. Clin. Diagn. Lab. Immunol., 3, 570-574.
13. Chen, L.-C., Pirofski, L. & Casadevall, A. (1997), Extracellular proteins of Cryptococcus neoformans and host antibody response. Infect. Immun., 65, 2599-2605.
14. Cherniak, R., Morris, L.C., Belay, T., Spitzer, E.D. & Casadevall, A. (1995), Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect. Immun., 63, 1899-1905.
15. Cherniak, R. & Sundstrom, J.B. (1994), Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect. Immun., 62, 1507-1512.
16. Cleare, W. & Casadevall, A. (1998), The different binding patterns of two IgM monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlates with serotype classification and differences in functional assays. Clin. Diagn. Lab. Immunol. (in press).
17. Collins, H.L. & Bancroft, G.J. (1991), Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect. Immun., 59, 3883-3888.
18. Delfino, D., Cianci, L., Migliardo, M., Mancuso, G., Cusumano, V., Corradini, C. & Teti, G. (1996), Tumor necrosis factor-inducing activities of Cryptococcus neoformans componets. Infect. Immun., 64, 5199-5204.
19. DeShaw, M. & Pirofski, L.-A. (1995), Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV-individuals. Clin. Exp. Immunol., 99, 425-432.
20. Devi, S.J.N., Schneerson, R., Egan, W., Ulrich, T.J., Bryla, D., Robbins, J.B. & Bennett, J.E. (1991), Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun., 59, 3700-3707.
21. Devi, S.J.N. (1996), Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine, 14, 841-842.
22. Diamond, R.D. (1974), Antibody-dependent killing of Cryptococcus neoformans by human peripheral blood mononuclear cells. Nature, 247, 870-874.
23. Diamond, R.D. & Allison, A.C. (1976), Nature of the effector cells responsible for antibody-dependent cell-mediated killing of Cryptococcus neoformans. Infect. Immun., 14, 716-720.
24. Diamond, R.D. & Bennett, J.E. (1974), Prognostic factors in cryptococcal meningitis. Ann. Intern. Med., 80, 176-181.
25. Dong, Z.M. & Murphy, J.W. (1995), Effects of the two varieties of Cryptococcus neoformans cells and culture filtrate antigens on neutrophil locomotion. Infect. Immun., 63, 2632-2644.
26. Dong, Z.M. & Murphy, J.W. (1996), Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis receptor loss from the surface of human neutrophils. J. Clin. Invest., 97, 689-698.
27. Dong, Z.M. & Murphy, J.W. (1997), Cryptococcal polysaccharide bind to CD18 on human neutrophils. Infect. Immun., 65, 557-563.
28. Dromer, F., Charreire, J., Contrepois, A., Carbon, C. & Yeni, P. (1987), Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun., 55, 749-752.
29. Dromer, F., Aucouturier, P., Clauvel, J.-P., Saimot, G. & Yeni, P. (1988a), Cryptococcus neoformans antibody levels in patients with AIDS. Scan. J. Infect. Dis., 20, 283-285.
30. Dromer, F., Yeni, P. & Charreire, J. (1988b), Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice. Immunogenetics, 28, 417-424.
31. Dromer, F., Perrone, C., Barge, J., Vilde, J.L. & Yeni, P. (1989), Role of IgG and complement component C5 in the inital course of experimental cryptococcosis. Clin. Exp. Immunol., 78, 412-417.
32. Dromer, F. & Charreire, J. (1991), Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis., 163, 1114-1120.
33. Drouhet, E. & Segretain, G. (1951), Inhibition de la migration leucocytaire in vitro par un polyoside capsulaire de Torulopsis (Cryptococcus) neoformans. Ann. Inst. Pasteur, 81, 674.
34. Evans, E.E. (1960), Capsular reactions of Cryptococcus neoformans. Ann. N. Y. Acad. Sci., 89, 184-192.
35. Feldmesser, M., Mukherjee, J. & Casadevall, A. (1996), Combination of 5-flucytosine and capsule binding monoclonal antibody in therapy of murine Cryptococcus neoformans infections and in vitro. J. Antimicrob. Chemother., 37, 617-622.
36. Feldmesser, M., Casadevall, A., Kress, Y., Spira, G. & Orlofski, A. (1997), Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro. Infect. Immun., 65, 1899-1907.
37. Feldmesser, M., Kress, Y. & Casadevall, A. (1998), Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans. J. Infect. Dis., 177, 1639-1646.
38. Feldmesser, M. & Casadevall, A. (1997), Effect of serum IgG1 against murine pulmonary infection with Cryptococcus neoformans. J. Immunol., 158, 790-799.
39. French, D.L., Laskov, R. & Scharff, M.D. (1989), The role of somatic hypermutation in the generation of antibody diversity. Science, 244, 1152-1157.
40. Glatman-Freedman, A. & Casadevall, A. (1998), Serum therapy for tuberculosis revisited: a reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin. Microbiol. Rev. (in press).
41. Goldman, D., Lee, S.C. & Casadevall, A. (1994), Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect. Immun., 62, 4755-4761.
42. Goldman, D., Cho, Y., Zhao, M.-L., Casadevall, A. & Lee, S.C. (1996), Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. Am. J. Pathol., 148, 1275-1282.
43. Goldman, D.L., Lee, S.C. & Casadevall, A. (1995), Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect. Immun., 63, 3448-3453.
44. Goldman, D.L., Casadevall, A. & Zuckier, L.S. (1997), Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis : implications for passive immunotherapy. J. Med. Vet. Mycol., 35, 271-278.
45. Gordon, M.A. & Casadevall, A. (1995), Serum therapy of cryptococcal meningitis. Clin. Infect. Dis., 21, 1477-1479.
46. Gordon, M.A. & Lapa, E. (1964), Serum protein enhancement of antibiotic therapy in cryptococcosis. J. Infect. Dis., 114, 373-378.
47. Goren, M.B. (1967), Experimental murine cryptococcosis: effect of hyperimmunization to capsular polysaccharide. J. Immunol., 98, 914-922.
48. Goren, M.B. & Middlebrook, G.M. (1967), Protein conjugates of polysaccharide from Cryptococcus neoformans. J. Immunol., 98, 901-913.
49. Graybill, J.R. & Ahrens, J. (1981), Immunization and complement interaction in host defense against murine cryptococcosis. J. Reticuloendothelial Soc., 30, 347-357.
50. Griffin, F.M. (1980), Roles of macrophage Fc and C3b receptors in phagocytosis of immunologically coated Cryptococcus neoformans. Proc. Natl. Acad. Sci. USA, 78, 3853-3857.
51. Gupta, S., Ellis, M., Cesario, T., Ruhling, M. & Vayuvegula, B. (1987), Disseminated cryptococcal infection in a patient with hypogammaglobulinemia and normal T-cell function. Am. J. Med., 82, 129-131.
52. Hamilton, A.J., Figueroa, J.I., Jeavons, L. & Seaton, R.A. (1997), Recognition of cytoplasmic yeast antigens of Cryptococcus neoformans and Cryptococcus neoformans var. gattii by immune human sera. FEMS Immunol. Med. Microbiol., 17, 111-119.
53. Han, Y. & Cutler, J.E. (1995), Antibody response that protects against disseminated candidiasis. Infect. Immun., 63, 2714-2719.
54. Henderson, D.K., Bennett, J.E. & Huber, M.A, (1982), Long-lasting, specific immunologic unresponsiveness associated with cryptococcal meningitis. J. Clin. Invest., 69, 1185-1190.
55. Henderson, D.K., Kan, V.L. & Bennett, J.E. (1986), Tolerance to cryptococcal polysaccharide in cured cryptococcosis patients: failure of antibody secretion in vitro. Clin. Exp. Immunol., 65, 639-646.
56. Hirano, A., Zimmerman, H.M. & Levine, S. (1964), Fine structure of cerebral fluid accumulation. V. Transfer of fluid from extracellular compartments in acute phase of cryptococcal polysaccharide lesions. Arch. Neurol., 11, 632-641.
57. Hirano, A., Zimmerman, H.M. & Levine, S. (1965a), The fine structure of cerebral fluid accumulation. VII. Reactions of astrocytes to cryptococcal polysaccharide implantation. J. Neuropath. Exp. Neurol., 24, 386-396.
58. Hirano, A., Zimmerman, H.M. & Levine, S. (1965b), Fine structure of cerebral fluid accumulation. VI. Intracellular accumulation of fluid and cryptococcal polysaccharide in oligodendria. Arch. Neurol., 12, 189-196.
59. Hobbs, M.M., Perfect, J.R., Granger, D.L. & Durack, D.T. (1990), Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. Infect. Immun., 58, 2115-2119.
60. Iseki, M., Anzo, M., Yamashita, N. & Matsuo, N. (1994), Hyper-IgM immunodeficiency with disseminated cryptococcosis. Acta Paediatr., 83, 780-782.
61. Kakeya, H., Udono, H., Ikuno, N., Yamamoto, Y., Mitsutake, K., Miyazaki, T., Tomono, K., Koga, H., Tashiro, T., Nakayama, E. & Kohno, S. (1997), A 77-kilodalton protein of Cryptococcus neoformans, a member of the heat shock protien 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis. Infect. Immun., 65, 1653-1658.
62. Kalina, M., Kletter, Y. & Aronson, M. (1974), The interaction of phagocytes and the large-sized parasite Cryptococcus neoformans: cytochemical and ultrastructural study. Cell Tiss. Res., 152, 165-174.
63. Kozel, T.R., Gulley, W.F. & Cazin, J., Jr. (1977), Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness. Infect. Immun., 18, 701-707.
64. Kozel, T.R., Reiss, E. & Cherniak, R. (1980), Concomitant but not casual association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide. Infect. Immun., 29, 295-300.
65. Kozel, T.R., Pfrommer, G.S.T., Guerlain, A.S., Highison, B.A. & Highison, G.J. (1988), Role of the capsule in phagocytosis of Cryptococcus neoformans. Rev. Infect. Dis., 10, S436-S439.
66. Kozel, T.R. (1993), Opsonization and phagocytosis of Cryptococcus neoformans. Arch. Med. Res., 24, 211-218.
67. Kozel, T.R. (1996), Activation of the complement system by pathogenic fungi. Clin. Microbiol. Rev., 9, 34-46.
68. Kozel, T.R., deJong, B.C.H., Grinsell, M.M, MacGill, R.S. & Wall, K.K. (1998), Characterization of anti-capsular monoclonal antibodies that regulate activation of the complement system by Cryptococcus neoformans. Infect. Immun. (in press).
69. Kozel, T.R. & Cazin, J., Jr. (1972), Immune response to Cryptococcus neoformans soluble polysaccharide. Infect. Immun., 5, 35-41.
70. Kozel, T.R. & Gotschlich, E. (1982), The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J. Immunol., 129, 1675-1680.
71. Kyong, C.U., Virella, G., Fudenberg, H.H. & Darby, C.P. (1978), X-linked immunodeficiency with increased IgM: clinical, ethnic, and immunologic heterogeneity. Pediatr. Res., 12, 1024-1026.
72. Lee, E. & Rikihisa, Y. (1997), Anti-Ehelichia chaffeensis antibody complexed with E. chaffeensis induces potent proinflammatory cytokine mRNA expresssion in human monocytes through sustained reduction of IkB-alpha and activation of NF-kappaB. Infect. Immun., 2890-2897.
73. Lee, S.C., Kress, Y., Dickson, D.W. & Casadevall, A. (1995a), Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody. J. Neuroimmunol., 16, 152-161.
74. Lee, S.C., Casadevall, A. & Dickson, D.W. (1996), Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am. J. Pathol., 148, 1267-1274.
75. Lee, S.L., Kress, Y., Zhao, M.-L., Dickson, D.W. & Casadevall, A. (1995b), Cryptococcus neoformans survive and replicate in spacious phagosomes in human microglia. Lab. Invest., 73, 871-879.
76. Lendvai, N., Casadevall, A., Liang, Z., Goldman, D.L., Mukherjee, J. & Zuckier, L. (1998), Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J. Infect. Dis., 177, 1647-1659.
77. Levitz, S.M., Farrell, T.P. & Maziarz, R.T. (1991), Killing of Cryptococcus neoformans by human peripheral blood mononuclear cells stimulated in culture. J. Infect. Dis., 163, 1108-1113.
78. Macher, A.M., Bennett, J.E., Gadek, J.E. & Frank, M.M. (1978), Complement depletion in cryptococcal sepsis. J. Immunol., 120, 1686-1690.
79. Marquis, G., Montplaisir, S., Pelletier, M., Mousseau, S. & Auger, P. (1985), Genetic resistance to murine cryptococcosis: increased susceptibility in the CBA/N XID mutant strain of mice. Infect. Immun., 47, 282-287.
80. Marsch, C.B., Gadek, J.E., Kindt, G.C., Moore, S.A. & Wewers, M.D. (1995), Monocyte Fc-gamma receptor cross-linking induces IL-8 production. J. Immunol., 155, 3161-3167.
81. McGaw, T. & Kozel, T.R. (1979), Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide. Infect. Immun., 25, 262-267.
82. Merkel, G.J. & Scofield, B.A. (1997), The in vitro interaction of Cryptococcus neoformans with human lung epithelial cells. FEMS Immunol. Med. Microbiol., 19, 203-213.
83. Miller, G.P.G. & Kohl, S. (1983), Antibody-dependent leukocyte killing of Cryptococcus neoformans. J. Immunol., 131, 1455-1459.
84. Miller, M.F., Mitchell, T.G., Storkus, W.J. & Dawson, J.R. (1990), Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect. Immun., 58, 639-645.
85. Mozaffarian, N., Berman, J.W. & Casadevall, A. (1995), Immune complexes increase nitric oxide production by interferon-gamma-stimulated murine macrophage-like J774.16 cells. J. Leukoc. Biol., 57, 657-662.
86. Mozaffarian, N., Berman, J.W. & Casadevall, A. (1997), Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob. Agents Chemotherap., 41, 1825-1829.
87. Mukherjee, J., Scharff, M.D. & Casadevall, A. (1992), Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun., 60, 4534-4541.
88. Mukherjee, J., Casadevall, A. & Scharff, M.D. (1993a), Molecular characterization of the antibody responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J. Exp. Med., 177, 1105-1106.
89. Mukherjee, J., Pirofski, L., Scharff, M.D. & Casadevall, A. (1993b), Antibody mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl. Acad. Sci. USA, 90, 3636-3640.
90. Mukherjee, J., Zuckier, L., Scharff, M.D. & Casadevall, A. (1994), Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with Amphotericin B. Antimicrob. Agents Chemotherap., 38, 580-587.
91. Mukherjee, J., Cleare, W. & Casadevall, A. (1995a), Monoclonal antibody mediated capsular reactions (quellung) in Cryptococcus neoformans. J. Immunol. Meth., 184, 139-143.
92. Mukherjee, J., Feldmesser, M., Scharff, M.D. & Casadevall, A. (1995b), Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole activity. Antimicrob. Agents Chemotherap., 39, 1398-1405.
93. Mukherjee, J., Nussbaum, G., Scharff, M.D. & Casadevall, A. (1995c), Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. J. Exp. Med., 181, 405-409.
94. Mukherjee, S., Lee, S., Mukherjee, J., Scharff, M.D. & Casadevall, A. (1994), Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect. Immun., 62, 1079-1088.
95. Mukherjee, S., Lee, S.C. & Casadevall, A. (1995), Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun., 63, 573-579.
96. Mukherjee, S., Feldmesser, M. & Casadevall, A. (1996), J774 Murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J. Infect. Dis., 173, 1222-1231.
97. Murphy, J.W. (1993), Cytokine profiles associated with induction of the anticryptococcal cell-mediated immune response. Infect. Immun., 61, 4750-4759.
98. Murphy, J.W. & Cozad, G.C. (1972), Immunological unresponsiveness induced by cryptococcal polysaccharide assayed by the hemolytic plaque technique. Infect. Immun., 5, 896-901.
99. Nabavi, N. & Murphy, J.W. (1986), Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect. Immun., 51, 556-562.
100. Neill, J.M., Castillo, C.G., Smith, R.H. & Kapros, C.E. (1949), Capsular reactions and soluble antigens of Torula histolytica and Sporotrichum schenckii. J. Exp. Med., 89, 93-106.
101. Nosanchuk, J.D. & Casadevall, A. (1997), Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect. Immun., 65, 1836-1841.
102. Nussbaum, G., Yuan, R., Casadevall, A. & Scharff, M.D. (1996), Immunoglobulin G3 blocking antibodies to Cryptococcus neoformans. J. Exp. Med., 183, 1905-1909.
103. Nussbaum, G., Cleare, W., Casadevall, A., Scharff, M.D. & Valadon, P. (1997), Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J. Exp. Med., 185, 685-697.
104. Otteson, E.W., Welch, W.H. & Kozel, T.R. (1994), Protein-polysaccharide interactions. A monoclonal antibody specific for the capsular polysaccharide of Cryptococcus neoformans. J. Biol. Chem., 269, 1858-1864.
105. Papadimitriou, J.M., Robertson, T.A., Kletter, Y., Aronson, M. & Walters, M.N.-I. (1978), An ultrastructural examination of the interaction between macrophages and Cryptococcus neoformans. J. Path., 124, 103-109.
106. Perfect, J.R., Lang, S.D.R. & Durack, D.T. (1980), Chronic cryptococcal meningitis. Am. J. Path., 101, 177-193.
107. Pettoello-Mantovani, M., Casadevall, A., Kollman, T.R., Rubinstein, A. & Goldstein, H. (1992), Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet, 339, 21-23.
108. Pettoello-Mantovani, M., Casadevall, A., Smarnworawong, P. & Goldstein, H. (1994), HIV-1 Infectivity is increased in vitro by the presence of the capsular polysaccharide of Cryptococcus neoformans and Haemophilus influenzae. AIDS Hum. Retroviruses, 10, 1079-1087.
109. Pirofski, L., Lui, R., DeShaw, M., Kressel, A.B. & Zhong, Z. (1995), Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect. Immun., 63, 3005-3014.
110. Pirofski, L. & Casadevall, A. (1996), Antibody immunity to Cryptococcus neoformans: Paradigm for antibody immunity to the fungi? Zbl. Bakt., 284, 475-495.
111. Pirofski, L. & Casadevall, A. (1998), The use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol. Rev., 11, 1-26.
112. Retini, C., Vecchiarelli, A., Monari, C., Tascini, C., Bistoni, F. & Kozel, T.R. (1996), Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect. Immun., 64, 2897-2903.
113. Retini, C., Vecchiarelli, A., Monari, C., Bistoni, F. & Kozel, T.R. (1998), Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect. Immun., 66, 664-669.
114. Rhinehart-Jones, T.R., Fortier, A.H. & Elkins, K.L. (1994), Transfer of immunity against lethal murine Francisella infection by specific antibody depends of host gamma interferon and T cells. Infect. Immun., 62, 3129-3137.
115. Rhodes, J.C., Wicker, L.S. & Urba, W. (1980), Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect. Immun., 29, 494-499.
116. Sanford, J.E., Lupan, D.M., Schlagetter, A.M. & Kozel, T.R. (1990), Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun., 58, 1919-1923.
117. Sarosi, G.A., Parker, J.D., Doto, L.L. & Tosh, F.E. (1992), Amphotericin B in cryptococcal meningitis. Ann. Intern. Med., 71, 1079-1087.
118. Savoy, A.C., Lupan, D.M., Mananlo, P.B., Roberts, J.S., Schlageter, A.M., Weinhold, L.C. & Kozel, T.R. (1997), Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect. Immun., 65, 1800-1807.
119. Schlagetter, A.M. & Kozel, T.R. (1990), Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect. Immun., 58, 1914-1918.
120. Schneerson-Porat, S., Sharar, A. & Aronson, M. (1965), Formation of histiocyte rings in response to Cryptococcus neoformans infection. Res. J. Reticuloendothe. Soc., 2, 249-255.
121. Schwartz, D.A. (1988), Characterization of the biological activity of Cryptococcus infections in surgical pathology. The budding index and the carminophilic index. Ann. Clin. Lab. Sci., 18, 388-397.
122. Scott, E.N., Muchmore, H.G. & Felton, F.G. (1981), Enzyme-linked immunosorbent assays in murine cryptococcosis. Sabouraudia, 19, 257-265.
123. Shahar, A., Kletter, Y. & Aronson, M. (1969), Granuloma formation in cryptococcosis. Israel. J. Med. Sci., 5, 1164-1172.
124. Sundstrom, J.B. & Cherniak, R. (1993), T-cell dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A. Infect. Immun., 61, 1340-1345.
125. Tabone, M.-C., Leverger, G., Landman, J., Aznar, C., Boccon-Gibod, L. & Lasfargues, G. (1994), Disseminated lymphonodular cryptococcosis in a child with X-linked hyper-IgM immunodeficiency. Pediatr. Infect. Dis. J., 13, 77-79.
126. Valadon, P., Nussbaum, G., Boyd, L.F., Margulies, D.H. & Scharff, M.D. (1996), Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans. J. Mol. Biol., 261, 11-22.
127. Vazquez-Torres, A., Jones-Carson, J. & Balish, E. (1996), Peroxynitrite contributes to the candidacidal activity of nitric oxide-producing macrophages. Infect. Immun., 64, 3127-3133.
128. Vecchiarelli, A., Pietrella, D., Dottorini, M., Monari, C., Retini, C. & Todisco, T. (1994), Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin. Exp. Immunol., 98, 217-223.
129. Vecchiarelli, A., Retini, C., Pietrella, D., Monari, C., Tascini, C., Beccari, T. & Kozel, T.R. (1995), Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1beta secretion from human monocytes. Infect. Immun., 63, 2919-2923.
130. Vecchiarelli, A., Retini, C., Monari, C., Tascini, C., Bistoni, F. & Kozel, T.R. (1996), Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun., 64, 2846-2849.
131. Vecchiarelli, A., Monari, C., Retini, C., Pietrella, D., Palazzetti, B., Pitzurra, L. & Casadevall, A. (1998), Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. Eur. J. Immunol., 28, 114-121.
132. Vecchiarelli, A., Retini, C., Monari, C. & Casadevall, A. (1998), Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T cell proliferation. Infect. Immun. (in press).
133. Watabe, T., Miyaji, M. & Nishimura, K. (1984), Studies on the relationship between cysts and granulomas in murine cryptococcosis. Mycopathologia, 86, 113-120.
134. Williamson, P.R., Bennett, J.E., Polis, M.A., Robbins, J.B. & Schneerson, R. (1993), Immunogenicity and safety of a conjugate glucuronoxylomannan-tetanus conjugate vaccine in volunteers. Clin. Infect. Dis., 17, 540 [Abstract 56].
135. Young, A.C.M., Valadon, P., Casadevall, A., Scharff, M.D. & Sacchettini, J.C. (1997), The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implication for the identification of peptide mimotopes. J. Mol. Biol., 274, 622-634.
136. Yuan, R., Casadevall, A., Spira, G. & Scharff, M.D. (1995), Isotype switching from IgG3 to IgG1 converts a non-protective murine antibody to C. neoformans into a protective antibody. J. Immunol., 154, 1810-1816.
137. Yuan, R., Casadevall, A., Oh, J. & Scharff, M.D. (1997), T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl. Acad. Sci. USA, 94, 2483-2488.
138. Yuan, R., Clynes, R., Oh, J., Ravetch, J.V. & Scharff, M.D. (1998a), Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor function and IgG subclass. J. Exp. Med., 187, 1-8.
139. Yuan, R., Spira, G., Oh, J., Paizi, M., Casadevall, A. & Scharff, M.D. (1998b), Isotype switching increases antibody protective efficacy to Cryptococcus neoformans infection in mice. Infect. Immun., 66, 1057-1062.
140. Zhang, H., Zhong, Z. & Pirofski, L. (1997), Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Infect. Immun., 65, 1158-1164.
141. Zhong, Z. & Pirofski, L. (1998), Antifungal activity of a human anti-glucuronoxylomannan antibody. Clin. Diagn. Lab. Immunol., 5, 58-64.